Literature DB >> 20164033

Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis.

Marek Bielecki1, Krzysztof Kowal, Anna Lapinska, Justyna Chwiecko, Jan Skowronski, Stanislaw Sierakowski, Lech Chyczewski, Otylia Kowal-Bielecka.   

Abstract

Widespread vasculopathy and profound fibrosis are key features of the pathogenesis of systemic sclerosis (SSc). We hypothesized that the TNF-like weak inducer of apoptosis (TWEAK), a recently recognized multifunctional cytokine which regulates angiogenesis and tissue remodeling, may play a role in the development of SSc. The production of TWEAK by the peripheral blood mononuclear cells (PBMC) was investigated, by means of ELISA, in 24 SSc patients and 14 healthy subjects. Moreover, production of TWEAK was correlated with clinical features of SSc. PBMC were isolated using density gradient centrifugation on Histopaque and were cultured in FCS supplemented RPMI medium at 37 degrees C under 5% CO2. Production of TWEAK by PBMC was significantly diminished in patients with more severe microvascular damage, as indicated by the presence of "active" capillaroscopic pattern, compared with SSc patients with less pronounced microangiopathy ("slow" pattern), and healthy subjects. Moreover production of TWEAK correlated inversely with duration of Raynaud's phenomenon. PBMC from patients with scleroderma-related interstitial lung disease tended to produce lower amounts of TWEAK compared with SSc patients without lung involvement but the difference was not significant. The results of our study suggest that diminished production of TWEAK might play a role in the pathogenesis of vascular injury in SSc patients. Whether TWEAK may represent a new therapeutic target in SSc requires further studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20164033     DOI: 10.2478/v10042-009-0103-2

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  7 in total

1.  Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis.

Authors:  Waleed Ahmed Salah Eldeen Hassan; Eman Abd Elaleem Baraka; Basant Mohammed Elnady; Tahany Mahmoud Gouda; Nehad Fouad
Journal:  Eur J Rheumatol       Date:  2016-09-01

Review 2.  Biomarkers of scleroderma lung disease: recent progress.

Authors:  Faye N Hant; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

3.  Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease.

Authors:  Rizwan Masud; Khader Shameer; Aparna Dhar; Keyue Ding; Iftikhar J Kullo
Journal:  J Clin Bioinforma       Date:  2012-03-12

4.  Apoptosis modulation as a promising target for treatment of systemic sclerosis.

Authors:  Stéphane Chabaud; Véronique J Moulin
Journal:  Int J Rheumatol       Date:  2011-09-06

Review 5.  Updates on morphea: role of vascular injury and advances in treatment.

Authors:  Julio C Sartori-Valinotti; Megha M Tollefson; Ann M Reed
Journal:  Autoimmune Dis       Date:  2013-11-12

Review 6.  Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?

Authors:  Daniel Bertin; Delphine Stephan; Michel Khrestchatisky; Sophie Desplat-Jégo
Journal:  Front Immunol       Date:  2013-12-27       Impact factor: 7.561

7.  High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.

Authors:  Otylia Kowal-Bielecka; Marek Bielecki; Serena Guiducci; Beata Trzcinska-Butkiewicz; Małgorzata Michalska-Jakubus; Marco Matucci-Cerinic; Marek Brzosko; Dorota Krasowska; Lech Chyczewski; Krzysztof Kowal
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.